Get Premium to unlock powerful stock data
Zentalis Pharmaceuticals Inc logo

Zentalis Pharmaceuticals Inc

$ 24.75 +2.42 (+10.84%) 04:00 PM EST
P/E:
At Loss
P/B:
3.48
Market Cap:
$ 1.41B
Enterprise V:
$ 1.03B
Volume:
884.39K
Avg Vol (2M):
978.08K
Volume:
884.39K
Market Cap $:
1.41B
PE Ratio:
At Loss
Avg Vol (2-Month):
978.08K
Enterprise Value $:
1.03B
PB Ratio:
3.48
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%

Business Description

Zentalis Pharmaceuticals Inc
NAICS : 325411 SIC : 2833
1359 Broadway, Suite 1710, New York, NY, USA, 10018
Description
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.
Name Current Vs Industry Vs History
Cash-To-Debt 6.26
Equity-to-Asset 0.78
Debt-to-Equity 0.15
Debt-to-EBITDA -0.21
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 0
Distress
Grey
Safe
Beneish M-Score 0
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 52.27
9-Day RSI 47.25
14-Day RSI 43.54
6-1 Month Momentum % -71.19
12-1 Month Momentum % -59.92

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 6.93
Quick Ratio 6.93
Cash Ratio 6.65

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -36.1

Profitability Rank

Name Current Vs Industry Vs History
ROE % -53.65
ROA % -44.01
ROIC % -318.15
ROC (Joel Greenblatt) % -955.87
ROCE % -65.35

Financials (Next Earnings Date:2022-08-12 Est.)

ZNTL's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NAS:ZNTL

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Performance
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 0
EPS (TTM) ($) -3.85
Beta 0
Volatility % 66.89
14-Day RSI 43.54
14-Day ATR ($) 2.808068
20-Day SMA ($) 22.8745
12-1 Month Momentum % -59.92
52-Week Range ($) 17.33 - 87.19
Shares Outstanding (Mil) 56.96

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Zentalis Pharmaceuticals Inc Filings

Document Form Filing Date
No Filing Data

Headlines

See More